Clinical trials: Limited Stage
Fracture Femur, Fracture Tibia
Oral Supplementation With a Formulation Based on Cetylated Fatty Acids for Post-fracture Long Bone Healing
This clinical study aims to evaluate the potential benefits of a formulation based on Cetylated Fatty Acids in improving fracture healing of long bones in the lower limbs.
- Trial name
- CETIULTRA-BONE (NCT07299851)
- Testing
- CFA-based food supplement
- Where
- 6 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- Pharmanutra S.p.a.
Lung Cancer
Multinational Observational Study to Describe Diagnostic Stage Shift in Patients With Lung Cancer Using Medical Records
Multinational observational study to describe diagnostic stage shift in patients with lung cancer using medical records. Increased lung cancer screening programs and increased utilization of other screening modalities such as…
- Trial name
- DIASTAG (NCT06842056)
- Volunteers
- 3,000 people
- Sponsor
- AstraZeneca
Clear Cell Renal Cell Carcinoma
A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma
This is an open-label, multicenter, Phase 1a/1b study evaluating the theranostic pair 64Cu-PD-32766 Injection (PD-32766D) and 225Ac-PD-32766 Injection (PD-32766T) in adult patients with relapsed or refractory Carbonic Anhydrase…
- Trial name
- NCT07688187
- Testing
- PD-32766D (a Copper-64 [64Cu] labeled peptide), PD-32766T (an Actinium-225 [225Ac] labeled peptide)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- PeptiDream Inc.
Breast Neoplasms, Breast Cancer
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.
- Conditions
- Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
- Trial name
- NCT05113251
- Testing
- Trastuzumab Deruxtecan, Paclitaxel, Trastuzumab
- Where
- 145 sites in United States, Brazil and 16 more
- Volunteers
- 927 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Tissue Collection Study for Patients With Non-Small Cell Lung Cancer With Resectable Disease
A 15-gene lung signature was created to identify predictive and prognostic biomarkers for Non-Small Cell Lung Cancer (NSCLC) patients.
- Trial name
- NCT01450553
- Where
- 7 sites in United States
- Volunteers
- 450 people
- Sponsor
- Precision Therapeutics
Parkinson's Disease
A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy
This study will investigate the effect of TCH346 compared to placebo in delaying the need for symptomatic treatment with dopaminergic agents
- Trial name
- NCT00407212
- Testing
- TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)
- Where
- 45 sites in United States, Brazil and 7 more
- Volunteers
- 301 people
- Sponsor
- Novartis
Breast Cancer, TNBC - Triple-Negative Breast Cancer
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal residual disease (MRD), can lead to the cancer coming back later.
- Conditions
- Breast Cancer, TNBC - Triple-Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2 + Breast Cancer
- Trial name
- GEMINI Breast (NCT07211178)
- Testing
- There are no interventions in this observational study.
- Where
- 16 sites in United States
- Volunteers
- 900 people
- Sponsor
- Tempus AI
Lung Cancer, NSCLC
Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up
This registry is intended to measure the effect of myPlan Lung Cancer™ test has on treatment decisions of Surgeons when added to standard clinical-pathological parameters in patients with early stage NSCLC.The sponsor is…
- Conditions
- Lung Cancer, NSCLC, Lung Adenocarcinoma
- Trial name
- ONC003 (NCT02121925)
- Where
- United States
- Volunteers
- 227 people
- Sponsor
- Myriad Genetic Laboratories, Inc.
Lyme Disease
Detection of Borrelia Bacteria in Early Stage Lyme Borreliosis Using the T2Lyme Panel
The T2Lyme assay will be compared to Borrelia culture from erythema migrans (EM) biopsy and/or detection of the C6 antigen in serum collected prospectively from patients suspected of early Lyme disease.
- Trial name
- NCT03581279
- Testing
- T2Lyme Panel testing
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- T2 Biosystems
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - PAST Extension
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage Alzheimer's disease, based on…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- AMYPRED-PAST (NCT04851496)
- Where
- 4 sites in United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Breast Cancer
TAC Versus TC for Adjuvant Breast Cancer
The purpose of this research study is to find out what effects (good and bad) TC or TAC has on early stage HER2- breast cancer.
- Trial name
- NCT00493870
- Testing
- Docetaxel, Doxorubicin, Cyclophosphamide
- Where
- 95 sites in United States
- Volunteers
- 1,961 people
- Sponsor
- US Oncology Research
Osteosarcoma
A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Limited Stage of High-grade Osteosarcoma
This is a Phase 1+2, open-label, dose-escalation, and multidose study, aiming to investigate the safety, tolerability and pharmacokinetics of ZKAB001 (a fully human monoclonal antibody targeting the Programmed Death - Ligand 1…
- Trial name
- NCT03676985
- Testing
- ZKAB001 5mg/kg, ZKAB001 10mg/kg, ZKAB001 15mg/kg
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Lee's Pharmaceutical Limited
Chronic Pain
Evaluate the Use of the Foundation Pain Index and the Nutritional Supplement BioPlete™ in Adults With Chronic Pain
This study is a randomized, double-blind, placebo controllled parallel design study to evaluate the use of the Foundation Pain Index and the Nutritional Supplement BioPlete™ on quality of life in adults with chronic pain.
- Trial name
- NCT05278533
- Testing
- BioPlete™ Advanced Formula
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Ethos Research & Development
Non-small Cell Lung Cancer
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
Lung cancer remains the most frequent cause of cancer death in both men and women in the world. Surgical resection using lobectomy with mediastinal lymph node dissection or sampling has been a standard of care for operable early…
- Trial name
- STARS (NCT00840749)
- Testing
- CyberKnife Stereotactic Radiotherapy, Surgery
- Where
- 19 sites in United States, China and 2 more
- Volunteers
- 36 people
- Sponsor
- Accuray Incorporated
Breast Cancer, Triple Negative Breast Neoplasms
A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer
The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug taxane, will improve the results of the treatment for early- stage Triple Negative Breast…
- Conditions
- Breast Cancer, Triple Negative Breast Neoplasms, Triple-Negative Breast Neoplasm, Triple-Negative Breast Cancer
- Trial name
- NCT02685306
- Testing
- Bavituximab, Taxane
- Sponsor
- Peregrine Pharmaceuticals
Small Cell Lung Cancer
Chemotherapy and Radiotherapy to Treat Patients With Limited Stage of Small Cell Lung Cancer (SCLC)
This is a multicenter, phase II, open-label trial to evaluate the efficacy of pemetrexed + carboplatin combined with thoracic radiotherapy in patients with Limited Stage of small cell lung cancer
- Trial name
- NCT00494026
- Testing
- pemetrexed, carboplatin, radiotherapy
- Where
- 12 sites in Italy, Poland and 2 more
- Volunteers
- 4 people
- Sponsor
- Eli Lilly and Company
Solid Tumor Cancer
SB-743921 In Patients With Solid Tumors
The purpose of this study is to find a dose of SB-743921 in adult patients with solid tumors or lymphoma who have progressed on standard therapy or who have relapsed.
- Trial name
- NCT00136513
- Testing
- SB-743921
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Pancreatic Cancer Stage I, Pancreatic Cancer Stage II
Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer
This is a case-control study to clinically validate the performance of a protein biomarker test to differentiate Stage I and Stage II pancreatic ductal adenocarcinoma (PDAC) patient samples from samples acquired from control…
- Conditions
- Pancreatic Cancer Stage I, Pancreatic Cancer Stage II, Cancer Diagnosis, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- CLARITI (NCT06947382)
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 1,066 people, healthy volunteers welcome
- Sponsor
- Immunovia, Inc.
Parkinson Disease
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease
The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients at early stage of the disease.
- Trial name
- NCT02847650
- Testing
- PF-06649751
- Where
- 37 sites in United States, France and 2 more
- Volunteers
- 57 people
- Sponsor
- Pfizer
Healthy
Clinical Trial of GX-I7 in Healthy Volunteers
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GX-I7 in healthy volunteers.
- Trial name
- NCT02860715
- Testing
- GX-I7
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Genexine, Inc.